$3.55 Billion is the total value of BB BIOTECH AG's 30 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 11.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IONS | Buy | Ionis Pharmaceuticals Inc. | $409,258,000 | +2.7% | 8,136,334 | +3.5% | 11.52% | +4.4% |
| CELG | Buy | Celgene Corp | $357,360,000 | -23.0% | 3,424,298 | +7.5% | 10.06% | -21.7% |
| INCY | Buy | Incyte Corp. | $350,268,000 | -18.2% | 3,698,322 | +0.8% | 9.86% | -16.8% |
| NBIX | Sell | Neurocrine Biosciences Inc. | $267,899,000 | +26.2% | 3,452,753 | -0.3% | 7.54% | +28.4% |
| VRTX | Vertex Pharmaceuticals Inc. | $221,110,000 | -1.4% | 1,475,445 | 0.0% | 6.23% | +0.3% | |
| GILD | Gilead Sciences Inc. | $198,772,000 | -11.6% | 2,774,596 | 0.0% | 5.60% | -10.1% | |
| RDUS | Buy | Radius Health Inc. | $181,051,000 | -14.6% | 5,698,799 | +3.6% | 5.10% | -13.1% |
| HALO | Sell | Halozyme Therapeutics Inc. | $172,618,000 | +15.2% | 8,520,137 | -1.2% | 4.86% | +17.2% |
| SAGE | Sell | Sage Therapeutics Inc. | $171,700,000 | +152.3% | 1,042,439 | -4.6% | 4.84% | +156.6% |
| ALXN | Alexion Pharmaceuticals Inc. | $161,976,000 | -14.8% | 1,354,428 | 0.0% | 4.56% | -13.3% | |
| ESPR | Buy | Esperion Therapeutics Inc. | $155,578,000 | +48.0% | 2,362,964 | +12.6% | 4.38% | +50.5% |
| AGIO | Sell | Agios Pharmaceuticals Inc. | $155,502,000 | -15.3% | 2,719,998 | -1.1% | 4.38% | -13.8% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc. | $133,572,000 | +2.3% | 1,051,338 | -5.4% | 3.76% | +4.1% |
| JUNO | Sell | Juno Therapeutics Inc. | $87,992,000 | -4.6% | 1,925,000 | -6.3% | 2.48% | -2.9% |
| TSRO | Buy | Tesaro Inc. | $86,698,000 | -32.6% | 1,046,193 | +5.0% | 2.44% | -31.4% |
| REGN | Regeneron Pharmaceuticals Inc. | $77,072,000 | -15.9% | 205,000 | 0.0% | 2.17% | -14.5% | |
| MGNX | Buy | MacroGenics Inc. | $49,408,000 | +11.4% | 2,600,412 | +8.3% | 1.39% | +13.3% |
| AVXS | AveXis, Inc. | $44,578,000 | +14.4% | 402,800 | 0.0% | 1.26% | +16.3% | |
| MYOV | Buy | Myovant Sciences Ltd. | $44,340,000 | -17.6% | 3,507,882 | +0.9% | 1.25% | -16.1% |
| ITCI | Intra-Cellular Therapies Inc. | $31,856,000 | -8.2% | 2,200,000 | 0.0% | 0.90% | -6.7% | |
| WVE | New | Wave Life Sciences Ltd. | $30,049,000 | – | 856,096 | +100.0% | 0.85% | – |
| ICPT | Intercept Pharmaceuticals Inc. | $28,376,000 | +0.7% | 485,719 | 0.0% | 0.80% | +2.4% | |
| ALDR | Alder Biopharmaceuticals Inc. | $25,946,000 | -6.5% | 2,266,008 | 0.0% | 0.73% | -4.8% | |
| VYGR | New | Voyager Therapeutics Inc. | $25,556,000 | – | 1,539,520 | +100.0% | 0.72% | – |
| AKCA | New | Akcea Therapeutics, Inc. | $21,677,000 | – | 1,248,650 | +100.0% | 0.61% | – |
| FPRX | Buy | Five Prime Therapeutics Inc. | $18,139,000 | -43.0% | 827,500 | +6.4% | 0.51% | -42.0% |
| CDTX | Buy | Cidara Therapeutics Inc. | $15,608,000 | +44.3% | 2,295,272 | +71.9% | 0.44% | +47.2% |
| PRTA | Prothena Corp. PLC | $13,122,000 | -42.1% | 350,000 | 0.0% | 0.37% | -41.1% | |
| NVAX | Novavax Inc. | $10,329,000 | +8.8% | 8,330,000 | 0.0% | 0.29% | +10.6% | |
| ACHN | Achillion Pharmaceuticals Inc. | $3,684,000 | -35.9% | 1,279,340 | 0.0% | 0.10% | -34.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biotech Focus N V #1
- Biotech Invest N V #2
- Biotech Target N V #3
- Biotech Growth N V #4
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Celgene Corporation | 24 | Q1 2019 | 18.3% |
| Incyte Corporation | 24 | Q1 2019 | 15.3% |
| Gilead Sciences, Inc. | 24 | Q1 2019 | 14.2% |
| Vertex Pharmaceuticals Incorporated | 24 | Q1 2019 | 8.1% |
| Alexion Pharmaceuticals, Inc. | 24 | Q1 2019 | 5.7% |
| Halozyme Therapeutics, Inc. | 24 | Q1 2019 | 4.9% |
| Alnylam Pharmaceuticals, Inc. | 24 | Q1 2019 | 3.8% |
| Neurocrine Biosciences, Inc. | 23 | Q1 2019 | 10.3% |
| Regeneron Pharmaceuticals, Inc. | 22 | Q4 2018 | 3.5% |
| Achillion Pharmaceuticals, Inc. | 22 | Q3 2018 | 1.0% |
View BB BIOTECH AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Kezar Life Sciences, Inc. | February 14, 2023 | 3,000,000 | 4.4% |
| Mersana Therapeutics, Inc. | February 14, 2023 | 4,066,200 | 4.1% |
| Molecular Templates, Inc. | February 14, 2023 | 11 | 19.9% |
| Myovant Sciences Ltd. | February 14, 2023 | 5,872,639 | 6.0% |
| Scholar Rock Holding Corp | February 14, 2023 | 2,132,725 | 4.1% |
| Radius Health, Inc.Sold out | August 30, 2022 | 0 | 0.0% |
| Cidara Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| Voyager Therapeutics, Inc.Sold out | February 11, 2022 | 0 | 0.0% |
| HALOZYME THERAPEUTICS, INC. | February 12, 2021 | 3,970,000 | 2.9% |
| Intra-Cellular Therapies, Inc. | February 12, 2021 | 3,538,419 | 4.4% |
View BB BIOTECH AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 4 | 2024-04-04 |
| 13F-NT | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View BB BIOTECH AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.